Double maintains 1 strategies that include CHRS - Coherus BioSciences, Inc.
Current Value
$0.801 Year Return
Current Value
$0.801 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WSM | 45.93% | $19.62B | +2.40% | 1.80% |
W | 36.30% | $4.05B | -49.85% | 0.00% |
DLB | 36.17% | $7.77B | -3.32% | 1.57% |
KEYS | 35.19% | $25.93B | -2.41% | 0.00% |
TREX | 34.50% | $6.27B | -38.46% | 0.00% |
MTSI | 32.46% | $7.53B | +2.27% | 0.00% |
ZG | 32.21% | $16.51B | +48.79% | 0.00% |
SUNS | 32.18% | $146.29M | -3.54% | 8.38% |
AZTA | 32.08% | $1.56B | -41.99% | 0.00% |
FOR | 31.94% | $1.07B | -45.16% | 0.00% |
Z | 31.90% | $16.92B | +48.89% | 0.00% |
NCV | 31.64% | - | - | 4.73% |
PLAB | 31.33% | $1.30B | -27.06% | 0.00% |
TXG | 31.16% | $1.06B | -75.99% | 0.00% |
RGEN | 30.90% | $7.22B | -27.78% | 0.00% |
QS | 30.88% | $2.23B | -30.85% | 0.00% |
SLAB | 30.85% | $3.71B | -15.61% | 0.00% |
CRDO | 30.74% | $7.08B | +89.21% | 0.00% |
MSA | 30.58% | $5.77B | -22.89% | 1.40% |
AEIS | 30.24% | $3.59B | -3.08% | 0.43% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TCTM | -14.45% | $3.80M | -81.33% | 0.00% |
PG | -14.04% | $399.94B | +6.22% | 2.36% |
CBOE | -13.28% | $23.56B | +23.21% | 1.08% |
T | -12.21% | $204.43B | +62.56% | 3.91% |
ES | -12.16% | $22.79B | +4.76% | 4.65% |
DUK | -12.02% | $94.07B | +25.41% | 3.43% |
KR | -11.30% | $49.31B | +17.85% | 1.83% |
VZ | -10.78% | $191.04B | +6.68% | 5.93% |
VSTA | -10.69% | $366.38M | +15.99% | 0.00% |
CLX | -10.16% | $18.22B | -0.54% | 3.28% |
AEE | -9.84% | $27.20B | +36.41% | 2.69% |
SIGI | -9.57% | $5.59B | -12.39% | 1.60% |
AEP | -9.53% | $57.87B | +27.18% | 3.33% |
MVO | -9.23% | $63.94M | -50.31% | 23.82% |
EXC | -8.99% | $46.36B | +22.19% | 3.35% |
IEP | -8.76% | $4.74B | -46.04% | 33.76% |
AFL | -8.58% | $61.38B | +32.40% | 1.85% |
CME | -8.57% | $94.51B | +22.09% | 3.99% |
ALL | -8.35% | $54.99B | +20.26% | 1.82% |
MO | -8.30% | $99.39B | +36.94% | 6.89% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -28.33% | $414.68M | 1.43% |
VIXY | -20.94% | $195.31M | 0.85% |
TAIL | -15.22% | $86.59M | 0.59% |
CCOR | -14.29% | $64.32M | 1.18% |
XONE | -10.71% | $633.49M | 0.03% |
XHLF | -10.19% | $1.06B | 0.03% |
BOXX | -9.00% | $5.77B | 0.1949% |
UUP | -8.56% | $325.55M | 0.77% |
TBIL | -7.55% | $5.35B | 0.15% |
GBIL | -7.50% | $6.31B | 0.12% |
BIL | -6.95% | $41.05B | 0.1356% |
USDU | -6.86% | $207.14M | 0.5% |
IYK | -6.49% | $1.52B | 0.4% |
TBLL | -5.74% | $2.07B | 0.08% |
KMLM | -5.53% | $221.29M | 0.9% |
BILS | -5.08% | $3.65B | 0.1356% |
SPSK | -4.97% | $297.04M | 0.5% |
ICLO | -4.78% | $354.66M | 0.2% |
USFR | -4.41% | $18.50B | 0.15% |
IBMN | -4.12% | $473.37M | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VBK | 37.65% | $17.43B | 0.07% |
ARKG | 36.58% | $963.54M | 0.75% |
XBI | 36.40% | $5.07B | 0.35% |
IBUY | 35.53% | $152.97M | 0.65% |
QQQJ | 35.46% | $591.69M | 0.15% |
ITEQ | 35.40% | $85.58M | 0.75% |
KOMP | 35.34% | $1.94B | 0.2% |
METV | 35.14% | $276.15M | 0.59% |
IWO | 35.03% | $10.75B | 0.24% |
PBE | 34.88% | $229.91M | 0.58% |
IWC | 34.88% | $799.66M | 0.6% |
ESPO | 34.80% | $298.47M | 0.56% |
VXF | 34.65% | $20.01B | 0.05% |
XMHQ | 34.40% | $5.38B | 0.25% |
ARKK | 34.33% | $5.02B | 0.75% |
SECT | 34.32% | $1.83B | 0.78% |
IPO | 34.18% | $129.72M | 0.6% |
ISCG | 33.89% | $652.91M | 0.06% |
VFLO | 33.76% | $3.41B | 0.39% |
ONLN | 33.75% | $67.27M | 0.58% |
Yahoo
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the “Repurchases”) with certain holders (the “Holders”) of its 1.500% Convertible Senior Subordinated Notes due 2026 (the “Convertible Notes”), pursuant to which the Company agree
Finnhub
Page Not Found We are sorry, the page you requested cannot be found. Please check the URL or visit our Homepage. Attachments Original document ...
Yahoo
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation
Yahoo
The latest earnings release from Coherus BioSciences, Inc. ( NASDAQ:CHRS ) disappointed investors. We did some analysis...
SeekingAlpha
US equities finished the quarter higher, despite some volatility in December and a hawkish outlook from the US Fed. Click here to read the full commentary.
Yahoo
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTXG | 0.03% | $25.99M | 0.6% |
IBDQ | -0.06% | $3.18B | 0.1% |
WEAT | -0.25% | $115.01M | 0.28% |
MINT | 0.26% | $13.27B | 0.35% |
TFLO | -0.29% | $6.78B | 0.15% |
BAB | 0.30% | $973.70M | 0.28% |
IBTG | 0.41% | $1.82B | 0.07% |
GSY | 0.45% | $2.74B | 0.23% |
DUSB | 0.53% | $1.15B | 0.15% |
UTWO | 0.65% | $377.49M | 0.15% |
PALL | 0.68% | $373.36M | 0.6% |
FLDR | 0.81% | $774.80M | 0.15% |
FLTR | 0.82% | $2.42B | 0.14% |
GSST | -0.85% | $801.06M | 0.16% |
CLOA | -1.01% | $787.04M | 0.2% |
IAK | -1.15% | $792.77M | 0.39% |
FTSM | 1.23% | $6.38B | 0.45% |
CMBS | -1.24% | $433.51M | 0.25% |
SGOV | -1.26% | $39.39B | 0.09% |
ICSH | -1.34% | $5.66B | 0.08% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMX | 0.03% | $20.62B | -21.97% | 4.99% |
SJM | 0.06% | $12.61B | -3.69% | 3.62% |
AFG | -0.07% | $11.09B | +2.05% | 2.31% |
WHF | 0.07% | - | - | 16.18% |
AMH | -0.08% | $13.94B | +4.41% | 2.88% |
EVRG | -0.11% | $15.87B | +30.18% | 3.79% |
V | -0.12% | $676.62B | +24.39% | 0.65% |
IDA | -0.17% | $6.34B | +27.07% | 2.87% |
RYAM | 0.20% | $377.15M | +25.56% | 0.00% |
JKHY | 0.20% | $13.41B | +8.06% | 1.21% |
OLLI | -0.22% | $7.02B | +60.39% | 0.00% |
BF.B | -0.22% | $15.83B | -34.30% | 2.66% |
MCK | 0.22% | $84.43B | +26.33% | 0.41% |
RTX | 0.24% | $177.37B | +34.80% | 1.92% |
BTU | 0.29% | $1.64B | -44.32% | 2.25% |
NWE | -0.31% | $3.59B | +16.18% | 4.47% |
KDP | -0.36% | $47.45B | +13.10% | 2.58% |
LUMN | -0.39% | $3.94B | +172.34% | 0.00% |
GL | 0.41% | $11.00B | +18.35% | 0.73% |
CNA | -0.41% | $13.75B | +20.86% | 3.54% |